 |
 |
 |
 |
 |
 |
 |
|
|
NCCN Clinical Practice Guidelines in Oncology Symposium: Breast Cancer – Adjuvant Therapy: Chemotherapy, Hormonal TherapyRecorded at a symposium hosted by City of Hope on November 5, 2007 Presenter Robert W. Carlson, MD Dr. Carlson has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products and devices to be discussed in his presentation or who may financially support the educational activity. He has served as a paid consultant for AstraZeneca Pharmaceuticals LP, Genomic Health, Inc., and Pfizer Inc. He has served as a researcher for AstraZeneca Pharmaceuticals LP and Genentech, Inc. Dr. Carlson has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product. Program Overview The NCCN Clinical Practice Guidelines in Oncology™ consist of a comprehensive set of guidelines detailing the sequential management decisions and interventions for the malignancies that affect 97% of all patients with cancer. Developed by faculty at NCCN Member Institutions using a consensus-based process with explicit review of pertinent data, the guidelines panels develop over 100 separate pathways. The NCCN Breast Cancer Guidelines Panel has developed and continually updates algorithms for management of non-invasive and invasive breast cancer. This activity is an in-depth analysis of the evidence and clinical decision making that led to the development of these guidelines and will focus on the use of hormonal, cytotoxic and biologic therapies in the adjuvant and neoadjuvant settings. Educational Objectives Following this activity, participants should be able to:
Intended Audience This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer. Activity Instructions Continuing education credit will be awarded to participants who listen to the presentation and complete the evaluation. Participants should review the learning objectives and faculty disclosure statements prior to listening to a presentation in its entirety. You must be connected to the Internet in order to review and complete the evaluation form. A statement of credit will be electronically generated once you complete the evaluation form. To receive credit, this activity must be completed no later than December 17, 2008. There is no fee for participating in this activity. Accreditation Information Physicians The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. NCCN designates this educational activity for a maximum of 0.75 AMA PRA Category
1 Nurses This activity is approved for 0.8 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity. Release date: December 17, 2007 Commercial Support Distribution supported by educational grants from Abraxis BioScience, Inc., Amgen Oncology, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, GlaxoSmithKline, Novartis Oncology, Pfizer Inc., Roche Laboratories Inc., and sanofi-aventis U.S. |
|
NCCN 14th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™ |
|
|
